Curis (NASDAQ:CRIS) Given New $16.00 Price Target at HC Wainwright

Curis (NASDAQ:CRIS) had its price target lowered by HC Wainwright from $20.00 to $16.00 in a research report report published on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

Separately, StockNews.com began coverage on shares of Curis in a research report on Saturday. They set a “hold” rating on the stock.

Curis Price Performance

Shares of NASDAQ CRIS opened at $2.10 on Monday. The firm has a market cap of $17.78 million, a price-to-earnings ratio of -0.27 and a beta of 3.49. The stock’s fifty day moving average price is $3.01 and its two-hundred day moving average price is $3.86. Curis has a one year low of $2.10 and a one year high of $17.49.

Institutional Trading of Curis

A number of institutional investors have recently modified their holdings of CRIS. Squarepoint Ops LLC acquired a new position in Curis in the fourth quarter valued at about $35,000. Millennium Management LLC raised its position in shares of Curis by 92.6% in the 4th quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 12,287 shares in the last quarter. Focused Wealth Management Inc lifted its holdings in shares of Curis by 9.5% during the 4th quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock worth $181,000 after acquiring an additional 5,138 shares during the period. Geode Capital Management LLC boosted its position in shares of Curis by 27.3% during the 4th quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock worth $254,000 after acquiring an additional 17,820 shares in the last quarter. Finally, Alyeska Investment Group L.P. bought a new position in Curis in the fourth quarter valued at approximately $607,000. 29.97% of the stock is currently owned by institutional investors.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.